| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorobenzenes | 16 | 2014 | 32 | 2.140 |
Why?
|
| Sulfonamides | 16 | 2014 | 86 | 2.070 |
Why?
|
| Pyrimidines | 16 | 2014 | 80 | 2.050 |
Why?
|
| Heptanoic Acids | 10 | 2014 | 35 | 1.360 |
Why?
|
| Pyrroles | 10 | 2014 | 62 | 1.330 |
Why?
|
| Myocardial Infarction | 16 | 2016 | 515 | 1.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 17 | 2011 | 168 | 1.220 |
Why?
|
| Hypercholesterolemia | 10 | 2010 | 74 | 1.050 |
Why?
|
| Simvastatin | 10 | 2011 | 28 | 0.990 |
Why?
|
| Middle Aged | 83 | 2020 | 12707 | 0.970 |
Why?
|
| Cholesterol, LDL | 14 | 2009 | 185 | 0.970 |
Why?
|
| Treatment Outcome | 42 | 2021 | 3618 | 0.940 |
Why?
|
| Anticholesteremic Agents | 6 | 2012 | 47 | 0.930 |
Why?
|
| Stents | 9 | 2018 | 167 | 0.910 |
Why?
|
| Aged | 70 | 2020 | 11002 | 0.860 |
Why?
|
| Humans | 115 | 2021 | 34497 | 0.850 |
Why?
|
| Pulmonary Embolism | 2 | 2015 | 52 | 0.830 |
Why?
|
| Female | 90 | 2020 | 21499 | 0.810 |
Why?
|
| Femoral Artery | 6 | 2017 | 50 | 0.780 |
Why?
|
| Cardiovascular Diseases | 6 | 2014 | 1209 | 0.780 |
Why?
|
| Urinary Incontinence, Stress | 6 | 2005 | 75 | 0.750 |
Why?
|
| Male | 79 | 2020 | 20713 | 0.730 |
Why?
|
| Platelet Aggregation | 2 | 2019 | 31 | 0.650 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2016 | 94 | 0.630 |
Why?
|
| Time Factors | 25 | 2018 | 2352 | 0.610 |
Why?
|
| Adult | 39 | 2020 | 10019 | 0.610 |
Why?
|
| Antipsychotic Agents | 2 | 2019 | 32 | 0.590 |
Why?
|
| Retrospective Studies | 40 | 2018 | 3814 | 0.590 |
Why?
|
| Health Resources | 2 | 2018 | 35 | 0.570 |
Why?
|
| Huntington Disease | 4 | 2020 | 15 | 0.560 |
Why?
|
| Quality of Life | 9 | 2021 | 1032 | 0.560 |
Why?
|
| Prostheses and Implants | 4 | 2005 | 53 | 0.530 |
Why?
|
| Thrombolytic Therapy | 2 | 2015 | 67 | 0.520 |
Why?
|
| Risk Factors | 24 | 2018 | 4136 | 0.520 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 69 | 0.510 |
Why?
|
| Thrombectomy | 2 | 2015 | 75 | 0.510 |
Why?
|
| Drug Resistance | 1 | 2016 | 42 | 0.500 |
Why?
|
| Aspirin | 1 | 2016 | 65 | 0.490 |
Why?
|
| Dyslipidemias | 2 | 2014 | 61 | 0.480 |
Why?
|
| Stroke | 5 | 2016 | 700 | 0.470 |
Why?
|
| Antibodies, Monoclonal | 6 | 2021 | 270 | 0.470 |
Why?
|
| Analgesics, Opioid | 2 | 2018 | 265 | 0.470 |
Why?
|
| Catheterization, Peripheral | 2 | 2017 | 29 | 0.470 |
Why?
|
| Migraine Disorders | 3 | 2021 | 69 | 0.470 |
Why?
|
| Heart Neoplasms | 2 | 2014 | 20 | 0.460 |
Why?
|
| Embolectomy | 1 | 2015 | 6 | 0.450 |
Why?
|
| Myocarditis | 1 | 2015 | 9 | 0.450 |
Why?
|
| Brain Ischemia | 1 | 2016 | 160 | 0.450 |
Why?
|
| Clozapine | 1 | 2015 | 7 | 0.450 |
Why?
|
| Thrombosis | 2 | 2015 | 88 | 0.450 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2018 | 50 | 0.430 |
Why?
|
| Bone Wires | 1 | 2014 | 12 | 0.430 |
Why?
|
| Sternotomy | 1 | 2014 | 4 | 0.420 |
Why?
|
| Sutures | 1 | 2014 | 20 | 0.420 |
Why?
|
| Postural Balance | 2 | 2016 | 152 | 0.420 |
Why?
|
| Hemangioma | 1 | 2014 | 24 | 0.420 |
Why?
|
| Aortic Valve | 4 | 2018 | 60 | 0.420 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 66 | 0.410 |
Why?
|
| Polyesters | 1 | 2014 | 78 | 0.410 |
Why?
|
| Suture Techniques | 1 | 2014 | 61 | 0.410 |
Why?
|
| Heart Diseases | 1 | 2015 | 124 | 0.410 |
Why?
|
| Coronary Artery Disease | 6 | 2019 | 441 | 0.410 |
Why?
|
| Pesticides | 2 | 2016 | 201 | 0.400 |
Why?
|
| Occupational Exposure | 2 | 2016 | 237 | 0.390 |
Why?
|
| Drugs, Generic | 2 | 2010 | 15 | 0.380 |
Why?
|
| Emigrants and Immigrants | 2 | 2016 | 248 | 0.380 |
Why?
|
| Drug-Eluting Stents | 5 | 2011 | 14 | 0.380 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 164 | 0.380 |
Why?
|
| Transients and Migrants | 2 | 2016 | 304 | 0.380 |
Why?
|
| Coronary Restenosis | 5 | 2011 | 15 | 0.370 |
Why?
|
| Oseltamivir | 1 | 2012 | 6 | 0.360 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 44 | 0.350 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 51 | 0.350 |
Why?
|
| Aorta, Abdominal | 1 | 2011 | 33 | 0.350 |
Why?
|
| Antiviral Agents | 1 | 2012 | 110 | 0.340 |
Why?
|
| Iliac Artery | 1 | 2011 | 55 | 0.340 |
Why?
|
| Preventive Health Services | 1 | 2011 | 39 | 0.340 |
Why?
|
| Cesarean Section | 4 | 2010 | 122 | 0.330 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2010 | 9 | 0.320 |
Why?
|
| Influenza, Human | 1 | 2012 | 133 | 0.320 |
Why?
|
| Intraoperative Complications | 2 | 2010 | 62 | 0.320 |
Why?
|
| Pravastatin | 3 | 2008 | 16 | 0.320 |
Why?
|
| Risk Assessment | 16 | 2018 | 1508 | 0.320 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2010 | 26 | 0.320 |
Why?
|
| Electric Countershock | 1 | 2010 | 18 | 0.310 |
Why?
|
| Hispanic Americans | 2 | 2016 | 948 | 0.310 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2020 | 9 | 0.310 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 101 | 0.300 |
Why?
|
| United States | 19 | 2019 | 4267 | 0.300 |
Why?
|
| Follow-Up Studies | 17 | 2020 | 2366 | 0.300 |
Why?
|
| Immunosuppressive Agents | 4 | 2020 | 251 | 0.300 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2010 | 83 | 0.300 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2011 | 65 | 0.290 |
Why?
|
| Aortic Valve Stenosis | 2 | 2020 | 41 | 0.290 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 703 | 0.280 |
Why?
|
| Chorea | 2 | 2018 | 2 | 0.280 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2018 | 28 | 0.280 |
Why?
|
| Urologic Surgical Procedures | 2 | 2005 | 66 | 0.270 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 304 | 0.270 |
Why?
|
| Heart Valve Prosthesis | 2 | 2018 | 61 | 0.270 |
Why?
|
| Bioprosthesis | 2 | 2018 | 62 | 0.270 |
Why?
|
| Postoperative Complications | 6 | 2019 | 849 | 0.270 |
Why?
|
| Medication Adherence | 2 | 2020 | 163 | 0.270 |
Why?
|
| Piperidines | 2 | 2020 | 141 | 0.260 |
Why?
|
| Databases, Factual | 5 | 2018 | 378 | 0.260 |
Why?
|
| Aged, 80 and over | 15 | 2019 | 4152 | 0.250 |
Why?
|
| Echocardiography | 2 | 2020 | 202 | 0.240 |
Why?
|
| Prostatic Neoplasms | 6 | 2006 | 498 | 0.240 |
Why?
|
| Double-Blind Method | 6 | 2021 | 597 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 11 | 2013 | 197 | 0.240 |
Why?
|
| India | 4 | 2014 | 65 | 0.240 |
Why?
|
| Coronary Angiography | 4 | 2015 | 168 | 0.230 |
Why?
|
| Coronary Disease | 5 | 2007 | 239 | 0.230 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2018 | 109 | 0.230 |
Why?
|
| Fascia Lata | 1 | 2005 | 3 | 0.230 |
Why?
|
| Dehydration | 1 | 2005 | 9 | 0.230 |
Why?
|
| Solvents | 1 | 2005 | 6 | 0.230 |
Why?
|
| Urinary Retention | 1 | 2005 | 10 | 0.230 |
Why?
|
| Dermis | 1 | 2005 | 18 | 0.230 |
Why?
|
| Uterine Prolapse | 1 | 2005 | 21 | 0.220 |
Why?
|
| Age Factors | 6 | 2018 | 1262 | 0.220 |
Why?
|
| Incidence | 9 | 2019 | 1289 | 0.220 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 123 | 0.220 |
Why?
|
| Vascular Diseases | 4 | 2011 | 69 | 0.220 |
Why?
|
| Fibrinolytic Agents | 3 | 2015 | 71 | 0.210 |
Why?
|
| Severity of Illness Index | 9 | 2020 | 922 | 0.210 |
Why?
|
| Urinary Catheterization | 1 | 2004 | 23 | 0.210 |
Why?
|
| Hemorrhage | 3 | 2016 | 109 | 0.210 |
Why?
|
| Patient Satisfaction | 3 | 2020 | 245 | 0.210 |
Why?
|
| Postoperative Care | 1 | 2004 | 80 | 0.210 |
Why?
|
| Combined Modality Therapy | 6 | 2011 | 590 | 0.210 |
Why?
|
| Coronary Artery Bypass | 3 | 2013 | 112 | 0.200 |
Why?
|
| Endarterectomy, Carotid | 1 | 2003 | 29 | 0.200 |
Why?
|
| Heart Atria | 2 | 2014 | 84 | 0.200 |
Why?
|
| Angioplasty, Balloon | 1 | 2003 | 33 | 0.200 |
Why?
|
| Computer Simulation | 3 | 2014 | 256 | 0.200 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2013 | 34 | 0.190 |
Why?
|
| Radial Artery | 2 | 2013 | 16 | 0.190 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 803 | 0.180 |
Why?
|
| Cohort Studies | 13 | 2017 | 1910 | 0.180 |
Why?
|
| Logistic Models | 6 | 2018 | 808 | 0.180 |
Why?
|
| Coronary Thrombosis | 4 | 2010 | 14 | 0.180 |
Why?
|
| Immunoglobulin Fab Fragments | 3 | 2006 | 17 | 0.180 |
Why?
|
| Prostate-Specific Antigen | 3 | 2006 | 63 | 0.170 |
Why?
|
| Delivery, Obstetric | 4 | 2005 | 60 | 0.170 |
Why?
|
| Models, Biological | 2 | 2014 | 432 | 0.160 |
Why?
|
| Platelet Function Tests | 2 | 2019 | 8 | 0.160 |
Why?
|
| Acute Coronary Syndrome | 4 | 2011 | 210 | 0.160 |
Why?
|
| Pelvis | 3 | 2005 | 68 | 0.160 |
Why?
|
| Receptors, sigma | 1 | 2020 | 4 | 0.160 |
Why?
|
| Metals | 3 | 2010 | 20 | 0.160 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2013 | 184 | 0.150 |
Why?
|
| Bipolar Disorder | 1 | 2019 | 15 | 0.150 |
Why?
|
| Pulmonary Artery | 2 | 2018 | 27 | 0.150 |
Why?
|
| Schizophrenia | 1 | 2019 | 32 | 0.150 |
Why?
|
| Electrocardiography | 4 | 2012 | 657 | 0.150 |
Why?
|
| Depressive Disorder, Major | 1 | 2019 | 41 | 0.150 |
Why?
|
| Atherosclerosis | 3 | 2010 | 837 | 0.140 |
Why?
|
| ABO Blood-Group System | 1 | 2019 | 21 | 0.140 |
Why?
|
| Blood Platelets | 1 | 2019 | 61 | 0.140 |
Why?
|
| Thromboembolism | 1 | 2019 | 38 | 0.140 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 306 | 0.140 |
Why?
|
| Ventricular Function, Left | 3 | 2020 | 287 | 0.140 |
Why?
|
| Prosthesis Failure | 1 | 2018 | 58 | 0.140 |
Why?
|
| Patients | 1 | 2018 | 48 | 0.140 |
Why?
|
| Hirudins | 2 | 2016 | 19 | 0.140 |
Why?
|
| Anticoagulants | 3 | 2016 | 143 | 0.140 |
Why?
|
| Pulmonary Valve | 1 | 2018 | 12 | 0.140 |
Why?
|
| Young Adult | 3 | 2018 | 2827 | 0.140 |
Why?
|
| Aneurysm | 1 | 2018 | 21 | 0.140 |
Why?
|
| Tetrabenazine | 1 | 2018 | 3 | 0.140 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 31 | 0.140 |
Why?
|
| Pain, Postoperative | 2 | 2014 | 205 | 0.140 |
Why?
|
| Lovastatin | 4 | 2011 | 6 | 0.140 |
Why?
|
| Case-Control Studies | 5 | 2016 | 924 | 0.140 |
Why?
|
| Prosthesis Design | 4 | 2018 | 116 | 0.140 |
Why?
|
| Heparin | 2 | 2016 | 74 | 0.140 |
Why?
|
| Hemodynamics | 2 | 2018 | 168 | 0.130 |
Why?
|
| Caregivers | 1 | 2018 | 116 | 0.130 |
Why?
|
| Vascular Surgical Procedures | 1 | 2017 | 90 | 0.130 |
Why?
|
| Dopamine Agents | 1 | 2017 | 21 | 0.130 |
Why?
|
| Ohio | 1 | 2016 | 64 | 0.130 |
Why?
|
| Coronary Occlusion | 1 | 2016 | 1 | 0.120 |
Why?
|
| Comparative Effectiveness Research | 2 | 2016 | 29 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2007 | 46 | 0.120 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 350 | 0.120 |
Why?
|
| Twins, Monozygotic | 2 | 2006 | 13 | 0.120 |
Why?
|
| North Carolina | 4 | 2016 | 1612 | 0.120 |
Why?
|
| Physicians | 1 | 2018 | 167 | 0.120 |
Why?
|
| Anilides | 2 | 2005 | 12 | 0.120 |
Why?
|
| Saphenous Vein | 2 | 2005 | 22 | 0.120 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 627 | 0.120 |
Why?
|
| Androgen Antagonists | 2 | 2005 | 20 | 0.120 |
Why?
|
| Schizophrenia, Paranoid | 1 | 2015 | 2 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2016 | 430 | 0.110 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2015 | 1 | 0.110 |
Why?
|
| Cardiotonic Agents | 2 | 2013 | 52 | 0.110 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 23 | 0.110 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2005 | 47 | 0.110 |
Why?
|
| Peptides | 2 | 2006 | 142 | 0.110 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2015 | 27 | 0.110 |
Why?
|
| Image Enhancement | 1 | 2015 | 74 | 0.110 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 10 | 0.110 |
Why?
|
| Suction | 1 | 2014 | 10 | 0.110 |
Why?
|
| Niacinamide | 1 | 2014 | 8 | 0.110 |
Why?
|
| Fecal Incontinence | 2 | 2005 | 32 | 0.110 |
Why?
|
| Steel | 1 | 2014 | 2 | 0.110 |
Why?
|
| Diabetes Complications | 2 | 2008 | 189 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 1387 | 0.110 |
Why?
|
| Enoxaparin | 1 | 2014 | 21 | 0.110 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2005 | 50 | 0.110 |
Why?
|
| Pregnancy | 5 | 2010 | 1069 | 0.110 |
Why?
|
| Fatal Outcome | 1 | 2014 | 87 | 0.110 |
Why?
|
| Vena Cava, Inferior | 1 | 2014 | 30 | 0.100 |
Why?
|
| Angiography | 1 | 2014 | 79 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2015 | 114 | 0.100 |
Why?
|
| Sex Distribution | 2 | 2012 | 194 | 0.100 |
Why?
|
| Drainage | 1 | 2014 | 66 | 0.100 |
Why?
|
| Hydrazones | 1 | 2013 | 3 | 0.100 |
Why?
|
| Pyridazines | 1 | 2013 | 8 | 0.100 |
Why?
|
| Pregnancy, Multiple | 2 | 2003 | 10 | 0.100 |
Why?
|
| Equipment Design | 1 | 2014 | 192 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 196 | 0.100 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 100 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 176 | 0.100 |
Why?
|
| Heart Failure | 3 | 2018 | 780 | 0.100 |
Why?
|
| Hospital Costs | 1 | 2013 | 51 | 0.100 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2013 | 58 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 540 | 0.090 |
Why?
|
| Nitriles | 3 | 2007 | 26 | 0.090 |
Why?
|
| Preoperative Care | 3 | 2013 | 128 | 0.090 |
Why?
|
| Hospitals, Public | 1 | 2012 | 4 | 0.090 |
Why?
|
| Hospitals, Private | 1 | 2012 | 9 | 0.090 |
Why?
|
| Sex Factors | 2 | 2012 | 707 | 0.090 |
Why?
|
| Atherectomy | 1 | 2011 | 4 | 0.090 |
Why?
|
| Prognosis | 6 | 2020 | 1603 | 0.090 |
Why?
|
| Morbidity | 1 | 2011 | 103 | 0.090 |
Why?
|
| Age Distribution | 1 | 2012 | 211 | 0.090 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 26 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 68 | 0.090 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2011 | 46 | 0.090 |
Why?
|
| Health Care Costs | 2 | 2010 | 126 | 0.090 |
Why?
|
| Azetidines | 1 | 2011 | 11 | 0.090 |
Why?
|
| Niacin | 1 | 2011 | 7 | 0.080 |
Why?
|
| Laser Therapy | 1 | 2011 | 56 | 0.080 |
Why?
|
| Odds Ratio | 6 | 2007 | 480 | 0.080 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2007 | 38 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 129 | 0.080 |
Why?
|
| Hospital Mortality | 3 | 2009 | 207 | 0.080 |
Why?
|
| Adhesives | 1 | 2010 | 7 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2019 | 2461 | 0.080 |
Why?
|
| Triglycerides | 2 | 2008 | 249 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2007 | 803 | 0.080 |
Why?
|
| Population | 1 | 2009 | 8 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 200 | 0.080 |
Why?
|
| Professional Practice | 1 | 2009 | 28 | 0.080 |
Why?
|
| Parity | 2 | 2006 | 21 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 565 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2009 | 143 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2011 | 218 | 0.070 |
Why?
|
| Health Expenditures | 1 | 2010 | 71 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 189 | 0.070 |
Why?
|
| Hospitalization | 1 | 2012 | 500 | 0.070 |
Why?
|
| Exercise Therapy | 1 | 2011 | 283 | 0.070 |
Why?
|
| Diet | 1 | 2011 | 418 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 2011 | 216 | 0.070 |
Why?
|
| Exercise Test | 2 | 2015 | 247 | 0.070 |
Why?
|
| Diastole | 2 | 2008 | 100 | 0.070 |
Why?
|
| Stroke Volume | 4 | 2020 | 440 | 0.070 |
Why?
|
| Secondary Prevention | 2 | 2008 | 74 | 0.070 |
Why?
|
| British Columbia | 1 | 2008 | 1 | 0.070 |
Why?
|
| Prevalence | 6 | 2009 | 1034 | 0.070 |
Why?
|
| Apolipoproteins B | 1 | 2008 | 49 | 0.070 |
Why?
|
| Posture | 1 | 2008 | 63 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 378 | 0.070 |
Why?
|
| Apolipoprotein A-I | 1 | 2008 | 69 | 0.070 |
Why?
|
| Vagina | 2 | 2005 | 61 | 0.070 |
Why?
|
| Pulmonary Edema | 1 | 2008 | 13 | 0.070 |
Why?
|
| Adolescent | 3 | 2012 | 3801 | 0.070 |
Why?
|
| Immunization Programs | 1 | 2008 | 30 | 0.070 |
Why?
|
| Lipids | 1 | 2009 | 267 | 0.070 |
Why?
|
| Cholesterol, HDL | 1 | 2008 | 194 | 0.070 |
Why?
|
| Medicare | 1 | 2009 | 217 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2008 | 51 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2020 | 509 | 0.070 |
Why?
|
| Urodynamics | 2 | 2005 | 88 | 0.070 |
Why?
|
| Recurrence | 2 | 2005 | 295 | 0.070 |
Why?
|
| Length of Stay | 3 | 2017 | 335 | 0.070 |
Why?
|
| Hypertriglyceridemia | 1 | 2007 | 8 | 0.070 |
Why?
|
| Urinary Incontinence, Urge | 1 | 2007 | 5 | 0.060 |
Why?
|
| Triazoles | 1 | 2007 | 16 | 0.060 |
Why?
|
| Angina, Unstable | 1 | 2006 | 22 | 0.060 |
Why?
|
| Suburethral Slings | 1 | 2007 | 14 | 0.060 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 19 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2007 | 66 | 0.060 |
Why?
|
| Lung | 1 | 2008 | 279 | 0.060 |
Why?
|
| Echocardiography, Doppler | 2 | 2005 | 47 | 0.060 |
Why?
|
| Hemostasis, Surgical | 1 | 2006 | 12 | 0.060 |
Why?
|
| Hemostatic Techniques | 1 | 2006 | 7 | 0.060 |
Why?
|
| Urinary Incontinence | 2 | 2004 | 68 | 0.060 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2007 | 63 | 0.060 |
Why?
|
| Urology | 1 | 2006 | 33 | 0.060 |
Why?
|
| Contrast Media | 1 | 2006 | 148 | 0.060 |
Why?
|
| Lumbosacral Plexus | 1 | 2005 | 7 | 0.060 |
Why?
|
| Flutamide | 1 | 2005 | 5 | 0.060 |
Why?
|
| Postoperative Hemorrhage | 1 | 2006 | 41 | 0.060 |
Why?
|
| Data Collection | 1 | 2006 | 191 | 0.060 |
Why?
|
| Pelvic Pain | 1 | 2005 | 23 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2005 | 13 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2005 | 49 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2007 | 274 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2006 | 61 | 0.060 |
Why?
|
| Cyanates | 1 | 2005 | 1 | 0.060 |
Why?
|
| Respiration, Artificial | 3 | 2013 | 105 | 0.060 |
Why?
|
| Foreign-Body Reaction | 1 | 2005 | 4 | 0.060 |
Why?
|
| Dyspareunia | 1 | 2005 | 7 | 0.060 |
Why?
|
| Cross-Linking Reagents | 1 | 2005 | 17 | 0.060 |
Why?
|
| Rectocele | 1 | 2005 | 2 | 0.060 |
Why?
|
| Colposcopy | 1 | 2005 | 4 | 0.060 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 58 | 0.060 |
Why?
|
| Probability | 4 | 2006 | 168 | 0.060 |
Why?
|
| Nerve Block | 1 | 2005 | 63 | 0.060 |
Why?
|
| Sexual Behavior | 1 | 2006 | 129 | 0.060 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2005 | 73 | 0.050 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 153 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2005 | 58 | 0.050 |
Why?
|
| Valsalva Maneuver | 1 | 2004 | 3 | 0.050 |
Why?
|
| Life Tables | 1 | 2004 | 6 | 0.050 |
Why?
|
| Swine | 1 | 2005 | 230 | 0.050 |
Why?
|
| Sirolimus | 3 | 2011 | 34 | 0.050 |
Why?
|
| Actinomycosis | 1 | 2004 | 2 | 0.050 |
Why?
|
| Cystitis | 1 | 2004 | 8 | 0.050 |
Why?
|
| Paclitaxel | 3 | 2011 | 73 | 0.050 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2004 | 13 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2018 | 251 | 0.050 |
Why?
|
| Eosinophilia | 1 | 2004 | 11 | 0.050 |
Why?
|
| Electromyography | 1 | 2004 | 68 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 1607 | 0.050 |
Why?
|
| Punctures | 2 | 2017 | 35 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2004 | 74 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2006 | 249 | 0.050 |
Why?
|
| Collagen | 1 | 2005 | 239 | 0.050 |
Why?
|
| Reoperation | 1 | 2005 | 265 | 0.050 |
Why?
|
| Myocardial Revascularization | 3 | 2010 | 42 | 0.050 |
Why?
|
| Coronary Stenosis | 1 | 2003 | 31 | 0.050 |
Why?
|
| Puerperal Disorders | 1 | 2003 | 6 | 0.050 |
Why?
|
| Managed Care Programs | 3 | 2008 | 43 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2006 | 399 | 0.050 |
Why?
|
| Self Care | 1 | 2004 | 144 | 0.050 |
Why?
|
| Carotid Stenosis | 1 | 2003 | 61 | 0.050 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2005 | 202 | 0.050 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2003 | 87 | 0.050 |
Why?
|
| Registries | 3 | 2011 | 328 | 0.050 |
Why?
|
| Hypertension, Portal | 1 | 2002 | 10 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2020 | 438 | 0.050 |
Why?
|
| Hypertension, Pulmonary | 1 | 2002 | 23 | 0.050 |
Why?
|
| Liver Failure | 1 | 2002 | 22 | 0.050 |
Why?
|
| Obesity | 1 | 2010 | 1246 | 0.050 |
Why?
|
| Mothers | 1 | 2003 | 94 | 0.050 |
Why?
|
| Fibroma | 1 | 2002 | 12 | 0.050 |
Why?
|
| Comorbidity | 3 | 2010 | 596 | 0.050 |
Why?
|
| Health Status | 1 | 2004 | 411 | 0.050 |
Why?
|
| Calcinosis | 1 | 2003 | 150 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2016 | 281 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 325 | 0.040 |
Why?
|
| Academic Medical Centers | 2 | 2013 | 168 | 0.040 |
Why?
|
| Monte Carlo Method | 2 | 2011 | 25 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2005 | 515 | 0.040 |
Why?
|
| Reference Values | 3 | 2006 | 265 | 0.040 |
Why?
|
| Drug Therapy, Combination | 3 | 2006 | 318 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2020 | 37 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 934 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 755 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 34 | 0.040 |
Why?
|
| Schizophrenic Psychology | 1 | 2019 | 9 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2003 | 439 | 0.040 |
Why?
|
| Depression | 2 | 2018 | 458 | 0.040 |
Why?
|
| Survival Rate | 3 | 2006 | 925 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 1523 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2010 | 35 | 0.040 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2008 | 9 | 0.030 |
Why?
|
| Indoles | 2 | 2008 | 67 | 0.030 |
Why?
|
| Perception | 1 | 2018 | 107 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2011 | 323 | 0.030 |
Why?
|
| Health Services Research | 2 | 2008 | 82 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2009 | 155 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 69 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 267 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2017 | 214 | 0.030 |
Why?
|
| Tosyl Compounds | 2 | 2005 | 3 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2006 | 310 | 0.030 |
Why?
|
| Postmenopause | 2 | 2007 | 461 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2005 | 508 | 0.020 |
Why?
|
| Animals | 1 | 2005 | 8544 | 0.020 |
Why?
|
| Disease Progression | 2 | 2006 | 633 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 612 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2013 | 123 | 0.020 |
Why?
|
| American Heart Association | 1 | 2012 | 92 | 0.020 |
Why?
|
| Connective Tissue | 1 | 2011 | 5 | 0.020 |
Why?
|
| Sweden | 1 | 2011 | 17 | 0.020 |
Why?
|
| Microinjections | 1 | 2011 | 39 | 0.020 |
Why?
|
| Propensity Score | 1 | 2011 | 50 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2011 | 63 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 163 | 0.020 |
Why?
|
| Rural Health Services | 1 | 2011 | 31 | 0.020 |
Why?
|
| Medical Records | 1 | 2011 | 81 | 0.020 |
Why?
|
| Myocardium | 1 | 2011 | 199 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 43 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2010 | 28 | 0.020 |
Why?
|
| Eligibility Determination | 1 | 2009 | 18 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 2010 | 57 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2009 | 22 | 0.020 |
Why?
|
| Lung Compliance | 1 | 2008 | 8 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 84 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 2008 | 24 | 0.020 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2008 | 12 | 0.020 |
Why?
|
| Platelet Count | 1 | 2008 | 25 | 0.020 |
Why?
|
| Hematocrit | 1 | 2008 | 23 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2008 | 19 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2008 | 49 | 0.020 |
Why?
|
| Leukocytes | 1 | 2008 | 61 | 0.020 |
Why?
|
| Goals | 1 | 2007 | 36 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 170 | 0.020 |
Why?
|
| Medical Audit | 1 | 2007 | 16 | 0.020 |
Why?
|
| Acute Disease | 1 | 2008 | 276 | 0.020 |
Why?
|
| Platelet Activation | 1 | 2006 | 18 | 0.020 |
Why?
|
| Markov Chains | 1 | 2007 | 32 | 0.020 |
Why?
|
| Drug Costs | 1 | 2007 | 51 | 0.020 |
Why?
|
| Creatinine | 1 | 2007 | 206 | 0.020 |
Why?
|
| Automation | 1 | 2006 | 30 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 37 | 0.020 |
Why?
|
| Injections | 1 | 2006 | 76 | 0.020 |
Why?
|
| Counseling | 1 | 2007 | 99 | 0.020 |
Why?
|
| Twin Studies as Topic | 1 | 2006 | 1 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2006 | 15 | 0.020 |
Why?
|
| National Health Programs | 1 | 2006 | 6 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2008 | 584 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 214 | 0.010 |
Why?
|
| Equipment Safety | 1 | 2006 | 21 | 0.010 |
Why?
|
| Premenopause | 1 | 2006 | 55 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2006 | 190 | 0.010 |
Why?
|
| Bupivacaine | 1 | 2005 | 60 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 429 | 0.010 |
Why?
|
| Health Surveys | 1 | 2005 | 202 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2005 | 104 | 0.010 |
Why?
|
| Linear Models | 1 | 2006 | 464 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2005 | 85 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2005 | 96 | 0.010 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2005 | 89 | 0.010 |
Why?
|
| Urethra | 1 | 2005 | 125 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 1354 | 0.010 |
Why?
|
| Hematuria | 1 | 2004 | 11 | 0.010 |
Why?
|
| Administration, Intravesical | 1 | 2004 | 28 | 0.010 |
Why?
|
| Cystoscopy | 1 | 2004 | 28 | 0.010 |
Why?
|
| Urination Disorders | 1 | 2004 | 18 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2005 | 136 | 0.010 |
Why?
|
| Abdominal Pain | 1 | 2004 | 44 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2005 | 385 | 0.010 |
Why?
|
| Triplets | 1 | 2003 | 1 | 0.010 |
Why?
|
| Twins | 1 | 2003 | 6 | 0.010 |
Why?
|
| Northwestern United States | 1 | 2003 | 1 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2003 | 69 | 0.010 |
Why?
|
| Adenosine | 1 | 2003 | 74 | 0.010 |
Why?
|
| Congresses as Topic | 1 | 2003 | 44 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 485 | 0.010 |
Why?
|
| Dobutamine | 1 | 2003 | 71 | 0.010 |
Why?
|
| Decision Making | 1 | 2005 | 203 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2003 | 214 | 0.010 |
Why?
|
| Anxiety | 1 | 2004 | 206 | 0.010 |
Why?
|
| Systole | 1 | 2002 | 103 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 954 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2002 | 61 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2002 | 185 | 0.010 |
Why?
|
| Hypertension | 1 | 2008 | 1024 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2002 | 901 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 986 | 0.010 |
Why?
|